Home  »  Companies   »  Analyzing the Price-to-Earnings Ratio of Nektar Th...

Analyzing the Price-to-Earnings Ratio of Nektar Therapeutics (NKTR)

The 36-month beta value for NKTR is also noteworthy at 1.17. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 7 rating it as “hold,” and 2 rating it as “sell.”

The public float for NKTR is 185.37M, and at present, short sellers hold a 4.72% of that float. The average trading volume of NKTR on March 15, 2023 was 2.05M shares.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


NKTR) stock’s latest price update

Nektar Therapeutics (NASDAQ: NKTR)’s stock price has decreased by 0.00 compared to its previous closing price of 1.20. Despite this, the company has seen a loss of -9.77% in its stock price over the last five trading days. The Wall Street Journal reported on 05/11/22 that This Biotech Flew High, Then Fell Hard When Its Cancer Drug Failed

NKTR’s Market Performance

NKTR’s stock has fallen by -9.77% in the past week, with a monthly drop of -59.04% and a quarterly drop of -57.14%. The volatility ratio for the week is 8.65% while the volatility levels for the last 30 days are 8.43% for Nektar Therapeutics The simple moving average for the last 20 days is -40.87% for NKTR stock, with a simple moving average of -63.68% for the last 200 days.

Analysts’ Opinion of NKTR

Many brokerage firms have already submitted their reports for NKTR stocks, with Jefferies repeating the rating for NKTR by listing it as a “Underperform.” The predicted price for NKTR in the upcoming period, according to Jefferies is $1.50 based on the research report published on February 24th of the current year 2023.

Jefferies gave a rating of “Hold” to NKTR, setting the target price at $4 in the report published on May 31st of the previous year.

NKTR Trading at -48.92% from the 50-Day Moving Average

After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.24% of loss for the given period.

Volatility was left at 8.43%, however, over the last 30 days, the volatility rate increased by 8.65%, as shares sank -61.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.45% lower at present.

During the last 5 trading sessions, NKTR fell by -9.77%, which changed the moving average for the period of 200-days by -65.32% in comparison to the 20-day moving average, which settled at $1.9355. In addition, Nektar Therapeutics saw -46.90% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NKTR starting from ROBIN HOWARD W, who sale 19,635 shares at the price of $3.00 back on Feb 16. After this action, ROBIN HOWARD W now owns 960,158 shares of Nektar Therapeutics, valued at $58,905 using the latest closing price.

Zalevsky Jonathan, the Chief R&D Officer of Nektar Therapeutics, sale 10,484 shares at $3.00 during a trade that took place back on Feb 16, which means that Zalevsky Jonathan is holding 303,179 shares at $31,452 based on the most recent closing price.

Stock Fundamentals for NKTR

Current profitability levels for the company are sitting at:

  • -260.97 for the present operating margin
  • +68.35 for the gross margin

The net margin for Nektar Therapeutics stands at -399.98. Equity return is now at value -79.80, with -43.60 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 8.00.


In summary, Nektar Therapeutics (NKTR) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.